Leukotrienes and Airway Inflammation

Overview

Journal Biochim Biophys Acta

Specialties Biochemistry
Biophysics

Date 2011 Mar 1

PMID 21352897

Citations 30

Authors

Katsuhide Okunishi

Marc Peters-Golden

Affiliations

Soon will be listed here.

Abstract

Background: Asthma is a common chronic inflammatory disease of the airways characterized by airway obstruction and hyperresponsiveness. Leukotrienes (LTs) are lipid mediators that contribute to many aspects of asthma pathogenesis. As the LT pathway is relatively steroid-resistant, its blockade by alternative strategies is a desirable component of asthma management. Cysteinyl LT (cysLT) receptor 1 antagonists (LTRAs) have been utilized worldwide for more than 10years, and while their efficacy in asthma is well accepted, their limitations are also evident.

Scope Of Review: In this review, we summarize the biological effects of LTs in asthma, review recent advances in LT receptors, and consider possible new therapeutic targets in the LT pathway that offer the potential to achieve better control of asthma in the future.

Major Conclusions: CysLTs play pathogenetic roles in many aspects of asthma, and blockade of cysLT receptor 1 by currently available LTRAs is certainly beneficial in disease management. On the other hand, the limitations of LTRAs are also apparent. Recent studies have revealed new receptors for cysLTs other than classical cysLT receptors 1 and 2, as well as the potential importance of LTB(4) in asthma.

General Significance: Recent findings provide clues to new approaches for targeting the LT pathway that may overcome the current limitations of LTRAs and achieve superior control of asthma. This article is part of a Special Issue entitled: Biochemistry of Asthma.

Citing Articles

Metabolomics Panel Associated with Cystic Fibrosis-Related Diabetes toward Biomarker Discovery.

Mujammami M, Nimer R, Al Mogren M, AlMalki R, Alabdaljabar M, Benabdelkamel H ACS Omega. 2024; 9(30):32873-32880.

PMID: 39100315 PMC: 11292812. DOI: 10.1021/acsomega.4c03626.

Leukotriene signaling as molecular correlate for cognitive heterogeneity in aging: an exploratory study.

Mrowetz H, Kotob M, Forster J, Aydin I, Unger M, Lubec J Front Aging Neurosci. 2023; 15:1140708.

PMID: 37600518 PMC: 10433382. DOI: 10.3389/fnagi.2023.1140708.

Ameliorative effect of montelukast against STZ induced diabetic nephropathy: targeting HMGB1, TLR4, NF-κB, NLRP3 inflammasome, and autophagy pathways.

Awad A, Elshaer S, Gangaraju R, Abdelaziz R, Nader M Inflammopharmacology. 2023; 32(1):495-508.

PMID: 37498374 PMC: 10907471. DOI: 10.1007/s10787-023-01301-1.

The combination of machine learning and untargeted metabolomics identifies the lipid metabolism -related gene CH25H as a potential biomarker in asthma.

Ding X, Qin J, Huang F, Feng F, Luo L Inflamm Res. 2023; 72(5):1099-1119.

PMID: 37081162 DOI: 10.1007/s00011-023-01732-0.

Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients.

Reina-Couto M, Roboredo-Madeira M, Pereira-Terra P, Silva-Pereira C, Martins S, Teixeira-Santos L Inflamm Res. 2023; 72(3):475-491.

PMID: 36617343 PMC: 9826622. DOI: 10.1007/s00011-022-01682-z.

References

Grant G, Rokach J, Powell W . 5-Oxo-ETE and the OXE receptor. Prostaglandins Other Lipid Mediat. 2009; 89(3-4):98-104. PMC: 2906239. DOI: 10.1016/j.prostaglandins.2009.05.002. View

Dahlen B, Nizankowska E, Szczeklik A, Zetterstrom O, Bochenek G, Kumlin M . Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med. 1998; 157(4 Pt 1):1187-94. DOI: 10.1164/ajrccm.157.4.9707089. View

Camargo Jr C, Gurner D, Smithline H, Chapela R, Fabbri L, Green S . A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J Allergy Clin Immunol. 2010; 125(2):374-80. DOI: 10.1016/j.jaci.2009.11.015. View

Yamaoka K, Kolb J . Leukotriene B4 induces interleukin 5 generation from human T lymphocytes. Eur J Immunol. 1993; 23(10):2392-8. DOI: 10.1002/eji.1830231003. View

Malaviya R, Ansell J, Hall L, Fahmy M, Argentieri R, Olini Jr G . Targeting cytosolic phospholipase A2 by arachidonyl trifluoromethyl ketone prevents chronic inflammation in mice. Eur J Pharmacol. 2006; 539(3):195-204. DOI: 10.1016/j.ejphar.2006.03.018. View

Bosse Y, Stankova J, Rola-Pleszczynski M . Cysteinyl-leukotrienes in asthmatic airway smooth muscle cell hyperplasia. Ann Allergy Asthma Immunol. 2009; 102(1):16-21. DOI: 10.1016/S1081-1206(10)60102-0. View

Peters-Golden M, Gleason M, Togias A . Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy. 2006; 36(6):689-703. PMC: 1569601. DOI: 10.1111/j.1365-2222.2006.02498.x. View

Busse W, Kraft M . Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest. 2005; 127(4):1312-26. DOI: 10.1378/chest.127.4.1312. View

Prinz I, Gregoire C, Mollenkopf H, Aguado E, Wang Y, Malissen M . The type 1 cysteinyl leukotriene receptor triggers calcium influx and chemotaxis in mouse alpha beta- and gamma delta effector T cells. J Immunol. 2005; 175(2):713-9. DOI: 10.4049/jimmunol.175.2.713. View

10.

Henderson Jr W, Tang L, Chu S, Tsao S, Chiang G, Jones F . A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002; 165(1):108-16. DOI: 10.1164/ajrccm.165.1.2105051. View

11.

Bautz F, Denzlinger C, Kanz L, Mohle R . Chemotaxis and transendothelial migration of CD34(+) hematopoietic progenitor cells induced by the inflammatory mediator leukotriene D4 are mediated by the 7-transmembrane receptor CysLT1. Blood. 2001; 97(11):3433-40. DOI: 10.1182/blood.v97.11.3433. View

12.

Mickleborough T, Lindley M, Ray S . Dietary salt, airway inflammation, and diffusion capacity in exercise-induced asthma. Med Sci Sports Exerc. 2005; 37(6):904-14. View

13.

Maekawa A, Balestrieri B, Austen K, Kanaoka Y . GPR17 is a negative regulator of the cysteinyl leukotriene 1 receptor response to leukotriene D4. Proc Natl Acad Sci U S A. 2009; 106(28):11685-90. PMC: 2710631. DOI: 10.1073/pnas.0905364106. View

14.

Miyahara N, Swanson B, Takeda K, Taube C, Miyahara S, Kodama T . Effector CD8+ T cells mediate inflammation and airway hyper-responsiveness. Nat Med. 2004; 10(8):865-9. DOI: 10.1038/nm1081. View

15.

Hallstrand T, Moody M, Wurfel M, Schwartz L, Henderson Jr W, Aitken M . Inflammatory basis of exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2005; 172(6):679-86. PMC: 2041799. DOI: 10.1164/rccm.200412-1667OC. View

16.

Nonaka Y, Hiramoto T, Fujita N . Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun. 2005; 337(1):281-8. DOI: 10.1016/j.bbrc.2005.09.052. View

17.

Wenzel S, Busse W, Calhoun W, Panettieri Jr R, Peters-Golden M, Dube L . The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study. J Asthma. 2007; 44(4):305-10. DOI: 10.1080/02770900701344199. View

18.

Parameswaran K, Cox G, Radford K, Janssen L, Sehmi R, OByrne P . Cysteinyl leukotrienes promote human airway smooth muscle migration. Am J Respir Crit Care Med. 2002; 166(5):738-42. DOI: 10.1164/rccm.200204-291OC. View

19.

Munoz N, Meliton A, Arm J, Bonventre J, Cho W, Leff A . Deletion of secretory group V phospholipase A2 attenuates cell migration and airway hyperresponsiveness in immunosensitized mice. J Immunol. 2007; 179(7):4800-7. DOI: 10.4049/jimmunol.179.7.4800. View

20.

Peters-Golden M, Henderson Jr W . Leukotrienes. N Engl J Med. 2007; 357(18):1841-54. DOI: 10.1056/NEJMra071371. View